Clinical Trial Update: A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating DZD8586 in relapsed or refractory B-cell non-Hodgkin lymphoma (TAI-SHAN1).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• DZD8586

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: COMPLETED